How Tirzepatide Is Prescribed in the UK: What the Evidence and Regulators Say

What NICE and the trial evidence actually say to prescribers

When a UK prescriber considers tirzepatide for weight management, they work within the framework NICE set out in Technology Appraisal TA1026. That appraisal drew heavily on the SURMOUNT clinical programme, particularly SURMOUNT-1, which enrolled 2,539 adults with obesity and ran for 72 weeks. At the highest dose, average body-weight reduction reached around 20–21%, figures that were markedly larger than anything seen with older treatments. NICE found the evidence credible enough to recommend tirzepatide as an option for NHS use, subject to the phased eligibility criteria NHS England has since introduced.

For prescribers, the TA translates into a practical checklist: confirmed BMI, documented comorbidities, ruling out contraindications, and an informed conversation about the escalating dose schedule and the lifestyle changes that must accompany treatment. The licence, granted by the MHRA, covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. NICE's NHS recommendation is narrower than the licence (BMI 35 and one comorbidity) but private prescribers can work to the full licensed criteria, assessed case by case. Prescribers working with people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds apply BMI thresholds that are 2.5 kg/m² lower under current UK guidance.

The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, went further: tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. That finding matters to prescribers choosing between available medicines, and it informs the clinical discussion at assessment.

What the prescribing process actually involves, step by step

A prescriber cannot simply write a tirzepatide prescription on request. The clinical assessment covers medical history, current medicines, BMI verified against the licensed or NICE threshold, and any conditions that could contraindicate treatment. Medullary thyroid carcinoma or a history of MEN2, severe GI disease, and a prior episode of pancreatitis all require careful evaluation. The NHS patient information for tirzepatide sets out the key interactions and warnings that sit behind that review.

Once a prescriber is satisfied, the prescription specifies the starting dose (2.5 mg) and sets out a titration plan. The 2.5 mg dose exists specifically to let the body adjust before the medicine does its main work; most people move through 5 mg, 7.5 mg and beyond over several months, with the prescriber reassessing at each stage. If a patient hasn't lost at least 5% of their body weight after six months at the highest tolerated dose, the guidance recommends reviewing whether continuing is appropriate. That review is itself a prescribing decision.

Prescribers also advise on injection technique, rotating sites between the abdomen, thigh and upper arm, and on storage, refrigeration is required, with a limited period permitted at room temperature; the exact window is in the Patient Information Leaflet, and prescribers direct patients there rather than paraphrasing it. Anyone considering private prescribing should know that a specific range of registered prescriber types are qualified to authorise tirzepatide in the UK.

NHS prescribing versus private prescribing: the practical differences

On the NHS, access follows the phased rollout NHS England announced following TA1026. From June 2025, the first cohort (adults with a BMI of 40 or above and four or more of five specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes)) became eligible. The second cohort, with BMI 35–39.9 and four or more of those conditions, was activated in June 2026. GP practices can prescribe under the 2026/27 QOF contract, though participation varies; many patients are still referred to specialist weight management services. Waiting times can be long, and not everyone meets the current phased criteria even if they hold the full licensed indication.

Private prescribers at GPhC-registered pharmacies like ours can work to the full licensed indication (BMI 30 or above, or 27 with a weight-related condition) assessed individually. The clinical assessment is equally rigorous; the difference is speed and the absence of a waiting list. Our prescribers review every consultation the same day, including identity and weight verification. If you're trying to understand whether getting tirzepatide through an online prescriber is a legitimate and safe route, the short answer is yes, provided the pharmacy is registered with the GPhC and uses a real clinician rather than an automated system. You can verify any pharmacy's registration at the GPhC register.

For context on what private treatment typically costs across providers, the cost of tirzepatide in the UK varies by dose and by what the service includes, consultation, prescription and aftercare are not always bundled in advertised prices, so it pays to read carefully.

What a prescriber cannot do, and why it protects you

A prescriber cannot supply tirzepatide without a prior assessment, cannot issue a repeat without reviewing whether treatment is still appropriate, and cannot prescribe to someone who is pregnant, breastfeeding or actively trying to conceive. Under-18s are outside the licence entirely. These are not bureaucratic hurdles; they reflect genuine clinical risks that the MHRA and the medicines' SmPCs are clear about.

Sellers offering tirzepatide pens without requiring a consultation, or with no evidence of a prescriber's involvement, are operating outside the law. If you want to understand where Mounjaro can legitimately be bought in the UK, the answer always involves a GPhC-registered pharmacy and a valid prescription. The MHRA has issued multiple warnings about counterfeit weight-loss pens (some containing insulin) and in 2025 seized approximately 20 million doses of illegally traded weight-loss medicines with a street value of around £45 million, including the UK's first raid on a site producing counterfeit tirzepatide pens. Report any suspect seller via the MHRA Yellow Card scheme.

If you're at the point of wanting to understand your own eligibility, the right next step is a consultation with a qualified prescriber, not a purchase. Our clinical team reviews every application personally, you can read more about our approach to clinical oversight on the about page. Patients who are unsure how to get tirzepatide through a proper clinical pathway will find a clear outline of the steps involved, from eligibility check through to dispensing. When you're ready, start your free consultation and a GPhC-registered prescriber will assess whether tirzepatide is the right option for you, issuing a prescription for tirzepatide if the clinical criteria are met.